On October 6, 2023 IngenOx Therapeutics, the Oxford-based biopharmaceutical company reported that it had received separate grants of applications from the Chinese (CNIPA); and European Patent Office for compounds and methods useful in the treatment of protein arginine methyl-transferase mediated proliferative disorders such as cancers (Press release, IngenOx Therapeutics, OCT 6, 2023, View Source [SID1234635681]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IngenOx is developing oral medicines which inhibit protein arginine methyltransferase 5 (PRMT5), an enzyme that is instrumental in driving the malignant properties of cancer cells. The enzyme methylates key targets which lead to uncontrolled cell growth and division, and inhibitors of PRMT5 are effective at blocking cancer cell proliferation. IngenOx has developed broad intellectual property and has received granted patents covering the PRMT5 enzyme and its inhibitors and is advancing them to clinical trials.
IngenOx’s granted China patent (No ZL201880031972.3) covers a range of tricyclic compounds suitable for use in the treatment of proliferative disorders. Its European patent (EP3596061) covers compounds useful in the treatment or prevention of a PRMT5-mediated disorder.
Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:
"We are delighted that the Chinese and European Patent Offices have granted patents on our applications, providing us with wide chemistry cover. The patents add to and extend our significant intellectual property and patent portfolio and strengthen our competitive position in this increasingly interesting area for cancer drug development. Combined with our precision medicine biomarker approach, we have a very powerful platform for delivering new and effective cancer drugs".